8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Oct 30, 2018)

Filed October 30, 2018For Securities:PFE

Summary

Pfizer Inc. (PFE) has filed an 8-K report on October 30, 2018, to announce its financial results for the third quarter of 2018. The report primarily furnishes a press release detailing these results, which is incorporated by reference. Investors should note that the information provided in this Item 2.02 and Exhibit 99 is furnished and not formally "filed" with the SEC, meaning it does not carry the same legal liabilities under Section 18 of the Exchange Act, unless specifically incorporated into other SEC filings. This filing serves as the official notification of Pfizer's Q3 2018 performance. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release (Exhibit 99) for comprehensive information on revenue, earnings, segment performance, and any forward-looking guidance provided by the company for the remainder of the fiscal year. Investors are encouraged to review the press release for a full understanding of Pfizer's operational and financial standing.

Key Highlights

  • 1Pfizer announced its third quarter 2018 financial results via a press release on October 30, 2018.
  • 2The 8-K filing incorporates the Q3 2018 earnings press release as Exhibit 99.
  • 3The furnished information is not considered "filed" for the purposes of Section 18 of the Exchange Act, limiting specific legal liabilities.
  • 4Investors should refer to the press release (Exhibit 99) for detailed financial performance data for Q3 2018.
  • 5The filing is a standard notification of material events, specifically the release of quarterly financial results.
  • 6No new material agreements, amendments, or other significant corporate events are detailed within the 8-K itself, only the financial results announcement.

Frequently Asked Questions

The actual financial results for Pfizer's third quarter of 2018 are detailed in the press release furnished as Exhibit 99 to this 8-K filing. You should refer to that document for specific figures on revenue, net income, earnings per share, and other financial metrics.

When information is "furnished" under Item 2.02 of an 8-K, it means the company is providing the information to the public but it is not subject to the same legal liability under Section 18 of the Securities Exchange Act of 1934 as if it were formally "filed." This is a common practice for earnings releases, but it's important for investors to understand this distinction.

This specific 8-K filing primarily serves to announce and incorporate Pfizer's Q3 2018 financial results. Any strategic announcements or updated financial guidance for the remainder of the fiscal year would be contained within the press release (Exhibit 99) itself, which should be reviewed for those details.

No, this 8-K filing is narrowly focused on the announcement of Pfizer's third quarter 2018 financial results. The core details of the financial performance, including operational results and financial condition, are presented in the accompanying press release (Exhibit 99).